Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting.

Literature DB >> 24251159

A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting.

Debmalya Sanyal¹, Soumava Gupta, Pratik Das.

Abstract

New-onset diabetes after transplantation (NODAT) is frequently encountered after kidney transplant. In the present study, we retrospectively evaluated the safety and efficacy of linagliptin monotherapy in 21 renal transplant recipients in a real world setting. We found linagliptin monotherapy is effective for glycemic control in NODAT, even on glucocorticoids and standard dose of tacrolimus. There was no alteration of tacrolimus drug levels or estimated glomerular filtration rate (eGFR) and minimal side effects, including weight gain and hypoglycemia. Well-designed, powered randomized controlled of antiglycemic agents in NODAT are needed.

Entities: Chemical Disease Gene Species

Keywords: Linagliptin; new-onset diabetes after transplantation; renal transplant

Year: 2013 PMID： 24251159 PMCID： PMC3830305 DOI： 10.4103/2230-8210.119572

Source DB: PubMed Journal: Indian J Endocrinol Metab ISSN： 2230-9500

8 in total

Review 1. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003.

Authors: Jaime Davidson; Alan Wilkinson; Jacques Dantal; Francesco Dotta; Hermann Haller; Domingo Hernández; Bertram L Kasiske; Bryce Kiberd; Andrew Krentz; Christophe Legendre; Piero Marchetti; Mariana Markell; Fokko J van der Woude; David C Wheeler
Journal: Transplantation Date: 2003-05-27 Impact factor: 4.939

2. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation.

Authors: James T Lane; David E Odegaard; Claire E Haire; Dean S Collier; Lucile E Wrenshall; R Brian Stevens
Journal: Transplantation Date: 2011-11-27 Impact factor: 4.939

3. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines.

Authors: Ebru Sulanc; James T Lane; Susan E Puumala; Gerald C Groggel; Lucille E Wrenshall; R Brian Stevens
Journal: Transplantation Date: 2005-10-15 Impact factor: 4.939

4. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).

Authors: U Graefe-Mody; C Friedrich; A Port; A Ring; S Retlich; T Heise; A Halabi; H-J Woerle
Journal: Diabetes Obes Metab Date: 2011-10 Impact factor: 6.577

5. Should metformin be our antiglycemic agent of choice post-transplantation?

Authors: A Sharif
Journal: Am J Transplant Date: 2011-05-12 Impact factor: 8.086

Review 6. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review.

Authors: C F Deacon
Journal: Diabetes Obes Metab Date: 2011-01 Impact factor: 6.577

7. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.

Authors: Stefan Blech; Eva Ludwig-Schwellinger; Eva Ulrike Gräfe-Mody; Barbara Withopf; Klaus Wagner
Journal: Drug Metab Dispos Date: 2010-01-19 Impact factor: 3.922

8. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

Authors: Janet B McGill; Lance Sloan; Jennifer Newman; Sanjay Patel; Christophe Sauce; Maximilian von Eynatten; Hans-Juergen Woerle
Journal: Diabetes Care Date: 2012-10-01 Impact factor: 19.112

8 in total

11 in total

Review 1. Diabetes in Kidney Transplantation.

Authors: Maria P Martinez Cantarin
Journal: Adv Chronic Kidney Dis Date: 2021-11 Impact factor: 3.620

Review 2. Emerging treatments for post-transplantation diabetes mellitus.

Authors: Trond Jenssen; Anders Hartmann
Journal: Nat Rev Nephrol Date: 2015-04-28 Impact factor: 28.314

Review 3. Diabetes Mellitus Following Renal Transplantation: Clinical and Pharmacological Considerations for the Elderly Patient.

Authors: David Langsford; Adam Steinberg; Karen M Dwyer
Journal: Drugs Aging Date: 2017-08 Impact factor: 4.271

A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting.

Review 1. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003.

2. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation.

3. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines.

4. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).

5. Should metformin be our antiglycemic agent of choice post-transplantation?

Review 6. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review.

7. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.

8. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

Review 1. Diabetes in Kidney Transplantation.

Review 2. Emerging treatments for post-transplantation diabetes mellitus.

Review 3. Diabetes Mellitus Following Renal Transplantation: Clinical and Pharmacological Considerations for the Elderly Patient.

Review 4. Management of the hospitalized transplant patient.

Review 5. The clinical application of linagliptin in Asians.

Review 6. Medical management of metabolic and cardiovascular complications after liver transplantation.

7. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation.

Review 8. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment.

Review 9. Post-Transplantation Diabetes Mellitus.

Review 10. Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients.